Chemistry:Sibrotuzumab

From HandWiki
Sibrotuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetFAP
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒N☑Y (what is this?)  (verify)

Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]

In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.[3]

References

  1. "A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer". Clinical Cancer Research 9 (5): 1639–47. May 2003. PMID 12738716. 
  2. "Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients". Investigational New Drugs 22 (1): 39–52. January 2004. doi:10.1023/B:DRUG.0000006173.72210.1c. PMID 14707493. 
  3. "Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer". Onkologie 26 (1): 44–8. February 2003. doi:10.1159/000069863. PMID 12624517.